SymBio Pharmaceuticals Reports Massive

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on January 16, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

SymBio Pharmaceuticals Reports Massive Exercise of Sixth-Fiveth Warrant Issue

Source disclosure: January 16, 2026 SymBio Pharmaceuticals Limited [4582.T] TOKYO, Jan 16 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) reported significant exercise activity of its sixth-fifth warrant issue during the period from January 16, 2026 through January 15, 2026. During this time, the company delivered 1,150,000 shares and exercised 1,150 warrants. As of December 31, 2025, there were 1,150,000 outstanding warrants, which decreased to 600,000 by January 15, 20